Skip to main content

Press Releases

ASH 2021: myCare-023 Finds Cellworks Personalized Biosimulation a Stronger Predictor of Therapy Response for AML Patients than Physician Prescribed Treatment

Results from myCare-023 Clinical Trial Featured in…

ASH 2021: Cellworks Personalized Therapy Biosimulation Study Identifies Novel Biomarkers Predictive of Response in AML Patients

AML Biomarker Identification Can Improve Clinical…

ASH 2021: Cellworks Personalized Therapy Biosimulation Study Identifies Novel Biomarkers Predictive of Response in Resistance Cases of MCL

Novel Biomarkers Can Help Identify Treatment…

ASH 2021: Cellworks Personalized Biosimulation Study Identifies Novel MDS Biomarkers and Immune Modulation Predictive of Therapy Response

Therapy Biosimulation Can Increase Success of…

WCLC 2021 : Cellworks Clinical Trial Results Presented at IASLC 2021
World Conference on Lung Cancer

Personalized Therapy Biosimulation Identifies Novel…

ASCO 2021 : Cellworks Singula™ Delivers Superior OS and DFS Predictions for Brain Cancer Patients in myCare-022-03 Clinical Trial

Personalized Therapy Biosimulation Using Multi-Omic…

ASCO 2021 : Cellworks CBM Clinical Study Identifies Novel Biomarkers for ATRA Benefit and Failure in AML Patients

Personalized Therapy Biosimulation Predicts with…

ASCO 2021 : Cellworks Singula™ Accurately Predicts Clinical Outcome from Treatments in Patients with NSCLC

Personalized Therapy Biosimulation Using Multi-Omic…

ASH 2020 : Cellworks Personalized Biosimulation Clinical Trials Achieve 90% Therapy Response Prediction Accuracy for AML and MDS Patients

myCare-020-01 and myCare-020-02 studies show…

ASH 2020 : Cellworks Personalized Biosimulation Clinical Trial Predicted ATO and ATRA Therapy Response in APL Patients with 93% Accuracy

myCare-021-01 study found CBM has high accuracy for…

ASH 2020 : Cellworks CBM Biosimulation Identifies Genomic Causes for Induction Failure in AML Patients and Suggests Alternative Therapies

myCare-021-02 study discovers patient-specific…

ASH 2020 : Cellworks CBM Identifies Genomic Signatures Impacting HOXA Regulation that Determine Response for AML Patients with
Monosomy 7

myCare-021-04 study finds genetic signatures…

ASCO 2020 : myCare Clinical Studies Show Cellworks Singula™Achieves Superior Therapy Response Predictions for Brain Cancer Patients

Cellworks Multi-omics Biosimulation Delivers GBM…

ASCO 2020 : Cellworks Singula™ Predicts Personalized Therapy Responses for AML and MDS Patients with Higher Accuracy than Physician Prescribed Treatments

myCare Studies Show Cellworks Multi-omics…

ASCO 2020 : Cellworks Singula™ Predicts Personalized Therapy Responses for Pancreatic Cancer Patients with 94% Accuracy

myCare Study Shows Cellworks Multi-omics…

Blood Advances Publishes Cellworks Prospective Genomic Biosimulation Study that Predicts Cancer Therapy Response with 90% Accuracy

Study Uses NGS Data with Biosimulation to Predict…

ASCO 2019 : Cellworks myCare™ Clinical Trial Transforms NGS Data into Personalized Cancer Therapy Actions

New Trial Biosimulates Efficacy of Cancer Therapies…

ASH 2018 : Cellworks Study Predicted Non-Response to Azacitidine in MDS Patients with 100% Accuracy using AI-Driven Biosimulation

Analysis Uncovered Possible Mechanisms for AZA…

ASH 2018 : Cellworks AI-Driven Biosimulation Predicted Chemo-resistance in AML and MDS Patients with 90% Accuracy

Prospective Study Successfully Identified…

Cellworks to Present 10 Abstracts at 2018 American Society of Hematology Annual Meeting

ASH Abstracts Reveal How AI-Driven Biosimulation…

Former UnitedHealth Group Cancer Director Dr. Lee Newcomer Joins Cellworks Board of Directors

Leading Precision Medicine Company Adds to…

Dr. Allen Lichter Joins Cellworks Group Board of Directors

Former CEO of ASCO Elected to Board of Leading…

STAY INFORMED

Top